ArticleJACC. Case reports2026
First Reported Native Transcatheter Tricuspid Valve Replacement in Congenitally Corrected Transposition of the Great Arteries.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenitally corrected transposition of the great arteries (CC-TGA) can lead to severe systemic tricuspid regurgitation (TR). There is limited evidence on transcatheter tricuspid valve replacement (TTVR) in these patients. CASE SUMMARY: A 59-year-old woman with CC-TGA presented with symptomatic severe systemic TR. She was at high risk for surgery, and transcatheter interventions were considered by our heart team. TTVR on the systemic tricuspid valve was performed using a Sapien M3 valve (Edwards Lifesciences), and the systemic TR was eliminated. There were no complications, with significant symptomatic improvement at the 30-day follow-up. DISCUSSION: Transcatheter therapies in high-surgical risk adult CC-TGA patients are being increasingly investigated. This case shows that TTVR using a Sapien M3 valve is feasible in CC-TGA patients with symptomatic severe systemic TR. TAKE-HOME MESSAGE: TTVR with the Sapien M3 valve is a feasible and safe alternative in high-surgical risk CC-TGA patients with symptomatic systemic TR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.